XNAS · BMRN

+0.00% · +$0.0000 · Vol Not reported

Market closed · last close shown

BioMarin Pharmaceuticals Inc

PHARMACEUTICAL PREPARATIONS

$66.64

Card

Relationship Map

Veridion Score

BETALOW CONF · 6/6 factors

Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET · BMRN

Methodology

BMRN

BioMarin Pharmaceuticals Inc

Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET

59/100

NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100

Veridion Score

NEUTRAL · LOW confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: LOW · 6/6 factors with data · Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is BMRN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move BMRN next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 17
Score
Score moved +7
52/NEUTRAL -> 59/NEUTRAL
Veridion score historySource
Mar 14
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Mar 6
CongressChecking access
Daniel Goldman sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
May 10
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Oct 18
CongressChecking access
Josh Gottheimer sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 30
CongressChecking access
Gilbert Cisneros purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Oct 16
CongressChecking access
Josh Gottheimer purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Sep 15
CongressChecking access
Josh Gottheimer sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 16
CongressChecking access
Josh Gottheimer purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About BioMarin Pharmaceuticals Inc

PHARMACEUTICAL PREPARATIONS

Listed since

1999

Employees

Country

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$66.64

Last session

Day high

$66.64

Last session

Day low

$66.64

Last session

Previous close

$66.64

52W high

$70.24

-5.13% from high

52W low

$49.67

82% of range

Market cap

$13B

P/E

36.22×

EPS

$1.84

Beta

-0.11

Shares out

193.6M

Avg volume

VWAP

$66.64

Last session

Price history computed in-house

-4.18%

+11.83%

+32.75%

+16.02%

YTD

+12.13%

SMA 50 $59.76 · above

SMA 200 $56.94 · above

52W position 82%

BMRN overview

Veridion Score

Daily close · 2026-08-17

6 of 6 factors measured

Relationship mapTrace receipt-backed holders and filings around BMRN.Congress disclosuresOpen receipt and filing context for BMRN.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

BMRN insider activity

BioMarin Pharmaceuticals Inc

Score

Not evaluated

Pressure

Not evaluated

Filings

Buys / sells

0 / 0

Net value

Not evaluated

Insiders

Cluster

Not evaluated: the SEC filing index could not be read

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

No value-bearing Form 4 rows

The current Form 4 feed did not return value-bearing open-market rows for BMRN.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in BMRN

Congress tracker Open ticker disclosure ledger →

Ro KhannaSell

BMRN Common Stock · Transaction Mar 14, 2023 · Filed Apr 7, 2023 · Amount pending receipt enrichment

Official filing ↗

Daniel GoldmanSell

BMRN · Transaction Mar 6, 2023 · Filed Apr 17, 2023 · $1,001 to $15,000

Official filing ↗

Ro KhannaSell

BMRN Common Stock · Transaction May 10, 2022 · Filed Jun 10, 2022 · Amount pending receipt enrichment

Official filing ↗

Josh GottheimerSell

BMRN Common Stock · Transaction Oct 18, 2021 · Filed Nov 15, 2021 · Amount pending receipt enrichment

Official filing ↗

Gilbert CisnerosBuy

BMRN Common Stock · Transaction Dec 30, 2020 · Filed Jan 11, 2021 · Amount pending receipt enrichment

Official filing ↗

Federal contracts

BMRN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for BMRN in this window.

Lobbying spend

BMRN lobbying filings, year to date.

Registered lobbying filings matched to BioMarin Pharmaceuticals Inc.

$1.9M

Refresh interval: 12hSource: LDA disclosure filings

Health Issues Medicare/Medicaid Tariff (miscellaneous tariff bills) Medical/Disease Research/Clinical LabsBudget/Appropriations Health Issues Medicare/Medicaid Tariff (miscellaneous tariff bills) Taxation/Internal Revenue CodeTariff (miscellaneous tariff bills) Health Issues Medicare/Medicaid

Filing

$530.0K

BIOMARIN PHARMACEUTICAL INC.

Apr 20, 2026

Filing

$390.0K

BIOMARIN PHARMACEUTICAL INC.

Jan 20, 2026

Filing

$340.0K

BIOMARIN PHARMACEUTICAL INC.

Jul 20, 2026